Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

For comparison, PNH and IgAN affect around 10-20 and 25 people per million, respectively. Sales of Fabhalta were $22 million in the second quarter, with what Novartis has called "encouraging early ...

Fabhalta is already approved in the US, EU, and Japan as a therapy for paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disorder, and is the first oral alternative to injectable or infused ...

Three new drugs have been approved to treat anaemic patients suffering from Paroxysmal nocturnal haemoglobinuria ... and iptacopan (brand name Fabhalta), to be used by adults on its own.

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...